Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer

British Journal of Cancer

Volumn 114, Issue 10, 2016, Pages 1109-1116

  Seo, An Na ^a,b   Lee, Hee Jin ^a,c   Kim, Eun Joo ^a   Jang, Min Hye ^a   Kim, Yu Jung ^a,d   Kim, Jee Hyun ^a,d   Kim, Sung Won ^a,d   Ryu, Han Suk ^d   Park, In Ae ^d   Im, Seock Ah ^d   Gong, Gyungyub ^c   Jung, Kyung Hae ^c   Kim, Hee Jeong ^c   Park, So Yeon ^a,d  

^a Seoul National University Bundang Hospital   (South Korea)

^b Kyungpook National University   (South Korea)

^c Asan Medical Center   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

breast cancer; breast cancer stem cell; HER2; prognosis; trastuzumab

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CD24 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; ISOENZYME; RETINAL DEHYDROGENASE; TUMOR MARKER;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BREAST NEOPLASMS; CANCER STEM CELL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTOR, ERBB-2; RETINAL DEHYDROGENASE; SURVIVAL ANALYSIS; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84967156207     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.101     Document Type: Article

References (33)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100: 3983-3988.
2. Bagaria SP, Ray PS, Wang J, Kropcho L, Chung A, Sim MS, Shamonki JM, Martino S, Cui X, Giuliano AE. (2012). Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol. 19: 935-940.
3. Bedard PL, Cardoso F, Piccart-Gebhart MJ. (2009). Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia. 14: 55-66.
4. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K. (2008). Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 26: 5697-5704.
5. Clarke MF, Fuller M. (2006). Stem cells, and cancer: two faces of eve. Cell. 124: 1111-1115.
6. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45: 228-247.
7. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. (2007). ALDH1 is a marker of normal, and malignant human mammary stem cells, and a predictor of poor clinical outcome. Cell Stem Cell. 1: 555-567.
8. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. (2007). Predictors of resistance to preoperative trastuzumab, and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 13: 1198-1207.
9. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C. (2008). The CD44+/CD24 phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53.
10. Kakarala M, Wicha MS. (2008). Implications of the cancer stem-cell hypothesis for breast cancer prevention, and therapy. J Clin Oncol. 26: 2813-2820.
11. Korkaya H, Paulson A, Iovino F, Wicha MS. (2008). HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis, and invasion. Oncogene. 27: 6120-6130.
12. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, Ryu HS, Park SY. (2011). An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 104: 1730-1738.
13. Lee HJ, Park IA, Park SY, Seo AN, Lim B, Chai Y, Song IH, Kim NE, Kim JY, Yu JH, Ahn JH, Gong G. (2014). Two histopathologically different diseases: hormone receptor-positive, and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat. 145: 615-623.
14. Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ, Kim JH, Kim SW, Ryu HS, Park IA, Im SA, Gong G, Jung KH, Kim HJ, Park SY. (2014). Prognostic, and predictive values of EGFR overexpression, and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer. 112(1): 103-111.
15. Lee HJ, Seo AN, Kim EJ, Jang MH, Suh KJ, Ryu HS, Kim YJ, Kim JH, Im SA, Gong G, Jung KH, Park IA, Park SY. (2014). HER2 heterogeneity affects trastuzumab responses, and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol. 142: 755-766.
16. Lesniak D, Sabri S, Xu Y, Graham K, Bhatnagar P, Suresh M, Abdulkarim B. (2013). Spontaneous epithelial-mesenchymal transition, and resistance to HER-2-Targeted therapies in HER-2-positive luminal breast cancer. PLoS One 8: e71987.
17. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 100: 672-679.
18. Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF, Yang XJ, Zhang X, Cui YH, Bian XW, Yu SC. (2014). ALDH1A1 expression correlates with clinicopathologic features, and poor prognosis of breast cancer patients: a systematic review, and meta-Analysis. BMC Cancer. 14: 444.
19. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133: 704-715.
20. Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, Cufi S, Moreno JM, Corominas-Faja B, Urruticoechea A, Martin AG, Lopez-Bonet E, Menendez JA. (2013). Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle. 12: 225-245.
21. Mukohara T. (2011). Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci. 102: 1-8.
22. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. (2006). Mechanisms of disease: understanding resistance to HER2-Targeted therapy in human breast cancer. Nat Clin Pract Oncol. 3: 269-280.
23. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. (2010). Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers, and features of aggressive tumours in African breast cancer. Br J Cancer. 102: 369-375.
24. Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufi S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA. (2010). Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun. 397: 27-33.
25. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. (2010). Heterogeneity for stem cell-related markers according to tumor subtype, and histologic stage in breast cancer. Clin Cancer Res. 16: 876-887.
26. Polyak K, Hahn WC. (2006). Roots, and stems: stem cells in cancer. Nat Med. 12: 296-300.
27. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson M, Slamon DJ. (1993). Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis, and association of overexpression with increased risk of recurrent disease. Cancer Res. 53: 4960-4970.
28. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353: 1673-1684.
29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse, and survival with amplification of the HER-2/neu oncogene. Science. 235: 177-182.
30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344: 783-792.
31. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. (1989). HER-2/neu oncogene protein, and prognosis in breast cancer. J Clin Oncol. 7: 1120-1128.
32. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. (2009). Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel, and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 15: 4234-4241.
33. Zhou L, Jiang Y, Yan T, Di G, Shen Z, Shao Z, Lu J. (2010). The prognostic role of cancer stem cells in breast cancer: a meta-Analysis of published literatures. Breast Cancer Res Treat. 122: 795-801.